Bolstering National Health: Etana Biotechnologies Drives Domestic Vaccine production
Table of Contents
- 1. Bolstering National Health: Etana Biotechnologies Drives Domestic Vaccine production
- 2. What role does Etana Biotechnologies Indonesia play in bolstering Indonesia’s healthcare autonomy?
- 3. Advancing National Health: An Interview with Indra Lamora, Director of Etana Biotechnologies Indonesia
- 4. Etana Biotechnologies: Pioneering Domestic Vaccine Production in Indonesia
- 5. Indra, congratulations on Etana’s recent success with the PCV-13 vaccine. Can you tell us about the journey towards obtaining GMP certification and the NIE?
- 6. The PCV-13 vaccine now plays a crucial role in Indonesia’s national immunization program. How does this impact the nation’s health and your company’s mission?
- 7. Looking ahead, what are Etana’s top priorities for 2025?
- 8. Can you tell us about the dengue vaccine collaboration and the need for such partnerships?
- 9. Etana envisions itself as a catalyst for positive change in Indonesia’s healthcare system. What steps are you taking to achieve this?
- 10. What’s one message you’d like to share with our readers about the importance of domestic vaccine production?
Etana Biotechnologies Indonesia (Etana), a prominent force in the Indonesian biopharmaceutical landscape, is deeply committed to bolstering the nation’s healthcare autonomy by championing the production of domestic vaccines. This dedication is evidenced by their significant achievement in 2024: obtaining both Good medicine Manufacturing Practices (CPOB) certification and a Marketing Permit Number (NIE) for their PCV-13 vaccine. This crucial vaccine now plays a vital role in Indonesia’s national immunization program.
Indra Lamora, Director of Etana’s Anti-Infectious Business Unit, notes in a recent statement, “As a national biotechnology company, Etana is proud to have the government’s trust to supply the PCV-13 vaccine in the routine immunization program. With this government support, we are increasingly motivated to continue to innovate and develop biotechnology products and othre vaccines that are beneficial to society,”
The impact of this locally produced vaccine extends far beyond bolstering domestic immunization efforts. It promises to offer a more affordable and accessible solution for the community while simultaneously reducing reliance on imported vaccines.
Looking ahead, Etana is strategically focused on two key priorities for 2025. The first is ensuring a consistent supply of locally manufactured vaccines, particularly the PCV-13, to support the government’s immunization program. The second priority is focusing on developing and introducing innovative domestic vaccines, including both HPV and T vaccines, which align with the government’s expanded immunization initiatives.
“these two vaccines are a launch for the expansion of routine immunization by the government through the Ministry of Health with the aim of eliminating the incidence of cervical cancer and preventing the transmission of tuberculosis in Indonesia,” Indra explains.
Etana’s commitment to enhancing public health extends beyond existing vaccines. The company actively seeks out strategic partnerships to address emerging health challenges. A recent example is their collaboration with the University of Indonesia (UI) and the National Research and Innovation Agency (BRIN), which is supported by LPDP funding, to develop a domestic dengue vaccine.
“dengue fever is a serious public health problem in Indonesia. To overcome this problem,continuous efforts are needed between ministries,institutions,industry,and universities,” Indra emphasizes the need for a collaborative approach to tackling this critical public health issue.
Etana envisions itself as a catalyst for positive change in Indonesia’s healthcare system. the company is dedicated to working alongside the government to achieve national health goals,ultimately fostering a stronger and more resilient healthcare system for all.
“We are committed to continuing to support the government in achieving national health goals. We believe that by working together, we can build a stronger health system,” Indra concludes.
What role does Etana Biotechnologies Indonesia play in bolstering Indonesia’s healthcare autonomy?
Advancing National Health: An Interview with Indra Lamora, Director of Etana Biotechnologies Indonesia
Etana Biotechnologies: Pioneering Domestic Vaccine Production in Indonesia
In a meaningful move towards bolstering Indonesia’s healthcare autonomy, Etana Biotechnologies indonesia (Etana) has successfully obtained both Good Manufacturing Practices (GMP) certification and a Marketing Permit Number (NIE) for their PCV-13 vaccine. This locally produced vaccine has now been integrated into the national immunization programme. We sat down with Indra Lamora, Director of Etana’s Anti-Infectious Business Unit, to discuss this monumental achievement and Etana’s plans for the future.
Indra, congratulations on Etana’s recent success with the PCV-13 vaccine. Can you tell us about the journey towards obtaining GMP certification and the NIE?
Thank you. The journey has been rigorous but rewarding. Obtaining GMP certification and the NIE was a testament to our commitment to quality and safety. We worked tirelessly to meet national and international standards, ensuring our vaccine manufacturing process adheres to the highest production standards. The support from the government and our relentless pursuit of excellence were instrumental in achieving this milestone.
The PCV-13 vaccine now plays a crucial role in Indonesia’s national immunization program. How does this impact the nation’s health and your company’s mission?
this development signifies a significant step towards bolstering our nation’s health capacity. Locally produced vaccines offer more affordable and accessible solutions, reducing reliance on imports.At Etana, our mission is to enhance public health through innovation and collaboration. Seeing our vaccine protecting Indonesian children is vindication of our company’s purpose.
Looking ahead, what are Etana’s top priorities for 2025?
In 2025, we aim to ensure a consistent supply of vaccines, particularly the PCV-13, to support the government’s immunization program. Concurrently, we’re committed to developing and introducing innovative domestic vaccines, such as HPV and T vaccines, aligning with the government’s expanded immunization initiatives. This includes our recent collaboration with the University of Indonesia and BRIN on a dengue vaccine.
Can you tell us about the dengue vaccine collaboration and the need for such partnerships?
Dengue fever is a critical public health issue in Indonesia. To combat this, we’ve partnered with UI and BRIN to develop a domestic dengue vaccine. Our collaboration underscores the need for continuous efforts between ministries, institutions, industry, and universities. Through thes partnerships, we believe we can overcome serious health challenges more effectively.
Etana envisions itself as a catalyst for positive change in Indonesia’s healthcare system. What steps are you taking to achieve this?
We’re dedicated to working alongside the government to achieve national health goals.By fostering strategic partnerships and supporting ongoing health initiatives, we hope to build a stronger, more resilient healthcare system for all Indonesians. We believe that together, we can drive positive change in our country’s healthcare landscape.
Domestic vaccine production is not just about self-sufficiency; it’s about ensuring affordable, accessible healthcare for all. By supporting and investing in our domestic biopharmaceutical industry, we’re investing in a healthier, more resilient future for our nation.
